BlackRock Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

BlackRock Group’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$293K	Buy	21,651 +945	+5%	+$13.2K	﹤0.01%	2546
2016 Q3	$255K	Buy	20,706 +405	+2%	+$4.77K	﹤0.01%	2544
2016 Q2	$222K	Sell	20,301 -135	-0.7%	-$1.51K	﹤0.01%	2545
2016 Q1	$222K	Sell	20,436 -8,388	-29%	-$106K	﹤0.01%	2540
2015 Q4	$499K	Sell	28,824 -180	-0.6%	-$3.23K	﹤0.01%	2202
2015 Q3	$576K	Sell	29,004 -6,311	-18%	-$145K	﹤0.01%	2153
2015 Q2	$580K	Buy	35,315 +12,706	+56%	+$220K	﹤0.01%	2214
2015 Q1	$352K	Buy	22,609 +6,905	+44%	+$107K	﹤0.01%	2310
2014 Q4	$224K	Buy	15,704 +14,731	+1,514%	+$156K	﹤0.01%	2495
2014 Q3	$6K	Hold	973	–	–	﹤0.01%	2818
2014 Q2	$7K	Hold	973	–	–	﹤0.01%	2806
2014 Q1	$7K	Hold	973	–	–	﹤0.01%	2721
2013 Q4	$9K	Sell	973 -13,580	-93%	-$96.9K	﹤0.01%	2629
2013 Q3	$91K	Buy	14,553 +13,580	+1,396%	+$84.8K	﹤0.01%	2620
2013 Q2	$6K	Buy	+973	New	+$7.72K	﹤0.01%	2587

Other funds holding SCMP

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return

BlackRock Group's SCMP Position: Q4 2016 in Review

BlackRock Group increased its Sucampo Pharmaceuticals, Inc. (SCMP) stake by 4.6% in Q4 2016, buying an estimated $13.2K and bringing the position to 21,651 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

BlackRock Group first reported a position in SCMP in Q2 2013 and has held it in 15 quarters since. The position peaked at $580K in Q2 2015. 165 funds tracked by Wall St. Rank hold SCMP as of Q4 2016.

BlackRock Group held 21,651 shares of Sucampo Pharmaceuticals, Inc. worth $293K as of Q4 2016.
BlackRock Group bought 945 Sucampo Pharmaceuticals, Inc. shares in Q4 2016, an estimated $13.2K.
Sucampo Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2546 holding.
BlackRock Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's Sucampo Pharmaceuticals, Inc. position peaked at $580K in Q2 2015.
165 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.